$NPHC

NUTRA PHARMA CORP

CIK:0001119643|SEC Filings

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)

3 Months Ended

6 Months Ended

Jun. 30, 2026

Jun. 30, 2025

Jun. 30, 2026

Jun. 30, 2025

Income Statement [Abstract]

Net sales

$ 34,463

$ 84,532

$ 61,709

$ 158,506

Net sales to a related party

23,459

37,611

44,427

74,031

Cost of sales

(25,297)

(58,715)

(54,536)

(104,978)

Reserve for supplier advances for purchases

(5,000)

Gross profit

32,625

63,428

51,600

122,559

Operating expenses:

Payroll, benefits and related taxes

184,743

174,554

355,031

354,143

Professional fees

171,850

75,406

289,350

187,224

Consulting expenses

81,246

76,167

167,232

163,726

Other selling, general and administrative costs

30,250

27,830

54,700

57,814

Total operating expenses

468,089

353,957

866,313

762,907

Loss from operations

(435,464)

(290,529)

(814,713)

(640,348)

Other income (expenses)

Other income

2,305

8,750

2,305

58,750

Interest expense

(103,922)

(101,242)

(198,282)

(193,452)

Interest expense to related parties

(6,248)

(5,550)

(12,250)

(11,135)

Change in fair value of convertible notes and derivatives

(3,405,443)

704,622

(3,526,007)

(302,687)

Net gain on settlement of debt and accrued expenses

53,526

140,500

53,526

Total other expenses, net

(3,513,308)

660,106

(3,593,734)

(394,998)

Loss before income taxes

(3,948,772)

369,577

(4,408,447)

(1,035,346)

Provision for income taxes

Net (loss) income

$ (3,948,772)

$ 369,577

$ (4,408,447)

$ (1,035,346)

Net loss per share - basic

$ (0.00)

$ 0.00

$ (0.00)

Net loss per share - diluted

$ (0.00)

$ 0.00

$ (0.00)

Weighted average number of shares outstanding during the period - basic

8,066,882,434

7,743,036,280

8,039,312,159

7,710,251,385

Weighted average number of shares outstanding during the period - diluted

8,066,882,434

^[1]

37,727,786,152

^[1]

8,039,312,159

7,710,251,385

[1]	Includes potential common shares that are in excess of authorized shares.

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended			6 Months Ended		12 Months Ended
	Jun. 30, 2026	Mar. 31, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025	Dec. 31, 2025
Cash flows from operating activities:
Net loss	$ (3,948,772)		$ 369,577	$ (4,408,447)	$ (1,035,346)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in reserve for supplier advances for purchases					5,000
Net gain on settlement of debt and accrued expenses		$ (140,500)	(53,526)	(140,500)	(53,526)
Depreciation	2,358		3,163	4,859	5,308
Stock-based compensation				14,833	1,667
Amortization of convertible notes receivable discount					(3,750)
Change in fair value of convertible notes and derivatives	3,405,443		(704,622)	3,526,007	302,687
Amortization of loan discount				132,175	126,085
Amortization of operating lease right-of-use assets					44,462
Changes in operating assets and liabilities:
Increase in accounts receivable				(394)	(11,469)
Decrease (increase) in accounts receivable - related party, net				2,818	(3,655)
Decrease in inventory				3,952	9,038
Increase in other receivable					(100,000)
Increase in due from employee - related party, net	(9,511)			(9,511)
Increase in prepaid expenses and other current assets				(16,000)	(102,500)
(Decrease) increase in accounts payable				36,043	(8,678)
Increase in accrued expenses				127,853	66,402
Increase in accrued payroll due to officers				135,048	99,291
Increase in due to a related party					9,584
Increase (decrease) in accrued interest to related parties				12,250	1,798
Decrease in operating lease obligations					(45,774)
Net cash used in operating activities				(579,014)	(693,376)
Cash flows from investing activities:
Purchase of property and equipment					(26,052)
Convertible notes receivable advances					(25,000)
Net cash used in investing activities					(51,052)
Cash flows from financing activities:
Advances from related parties				254,057	290,258
Repayments to related parties				(73,000)	(145,352)
Proceeds from convertible notes				463,001	810,056
Repayment of convertible notes				(37,825)	(28,000)
Advances from notes payable				83,250
Repayments of notes payable				(122,650)	(139,912)
Net cash provided by financing activities				566,833	787,050
Net change in cash				(12,181)	42,622
Cash - beginning of period		$ 12,181		12,181	36,447	$ 36,447
Cash - end of period			$ 79,069		79,069	$ 12,181
Supplemental Cash Flow Information:
Cash paid for interest				3,816	46,222
Cash paid for income taxes
Non Cash Financing and Investing:
Common stock to be issued for stock based compensation				13,000
Common stock issued for settlement of debt				$ 12,000

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash		$ 12,181
Inventory, current portion	23,509	19,535
Other receivable	133,906	133,906
Convertible notes receivable, net of discount	30,500	30,500
Receivable from sale of Stemsation stocks, net
Investment in Stemsation stocks	17,600	17,600
Settlement receivables	160,084	160,084
Prepaid expenses and other current assets	49,499	35,332
Total current assets	463,119	459,583
Inventory, less current portion	91,244	99,170
Due from employee - related party, net	47,554	38,043
Property and equipment, net	20,946	25,805
Total assets	622,863	622,601
Current liabilities:
Accounts payable	889,624	853,581
Accrued expenses	2,314,136	2,186,283
Accrued payroll due to officers	2,027,893	1,892,845
Accrued interest to related parties	215,081	202,831
Due to related parties	1,773,851	1,592,794
Derivative liabilities	2,037,134	960,382
SBA notes payable, current portion	14,361	12,525
Total current liabilities	21,696,808	17,311,263
SBA notes payable, less current portion	134,808	136,644
Total liabilities	21,831,616	17,447,907
Commitments and Contingencies (Note 11)
Stockholders’ deficit:
Preferred stock, $0.001 par value, 20,000,000 shares authorized and 12,000,000 Series B Preferred shares authorized, issued and outstanding	12,000	12,000
Common stock, $0.001 par value, 12,000,000,000 shares authorized; 7,159,727,214 and 7,099,727,214 shares issued and outstanding, respectively	7,159,727	7,099,727
Common stock to be issued	514,678	501,678
Additional paid-in capital	53,791,818	53,839,818
Accumulated deficit	(82,686,976)	(78,278,529)
Total stockholders’ deficit	(21,208,753)	(16,825,306)
Total liabilities and stockholders’ deficit	622,863	622,601
Nonrelated Party [Member]
Current assets:
Accounts receivable	26,454	26,060
Current liabilities:
Convertible notes payable, at fair value	4,495,723	2,046,469
Related Party [Member]
Current assets:
Accounts receivable	21,567	24,385
Unrelated Third Parties [Member]
Current liabilities:
Notes payable – Unrelated third parties, net	1,114,321	1,129,247
Convertible notes payable, at fair value	6,589,684	6,209,306
Other advances from an unrelated third party	$ 225,000	$ 225,000